The patient who needs immediate assistance should not communicate directly with the researcher. Instead, they should call the doctor’s office or take other appropriate measures, such as going to the nearest emergency service.


Assistant professor Faculty of pharmacy, Université de Montréal

Research Chair

Chairholder Chaire pharmaceutique Famille Jean-Guy Sabourin en santé des femmes de l'Université de Montréal / Jean-Guy Sabourin Family Pharmaceutical Chair in Women's Health ICM, Faculty of Pharmacy, Université de Montréal

Research Interests

John Stagg is Professor at the Faculty of Pharmacy of University of Montreal and Lab Head at the CRCHUM since 2010. An established cancer immunologist, Dr. Stagg cumulates over 100 research publications. Dr Stagg is known for having identified the adenosine-producing enzyme CD73 as a novel target in immuno-oncology and for contributing to the development of therapeutic agents now in Phase 2 clinical trials. Dr. Stagg is also co-founder and SAB member of Surface Oncology, a clinical-stage biotech, and member of the board of directors of BioCanRx, Canada’s immunotherapy network.

The Stagg lab has also identified novel potential targets in immune-oncology to overcome resistance to anti-PD-1/CTLA-4 immune checkpoint blockade. The Stagg lab uses state-of-the-

technologies to study tumor immunity, including bulk and single-cell RNAseq, flow cytometry, metabolomics, spatial omics and deep learning.

The Stagg lab is funded by CIHR, FRQS, the Terry Fox Research Institute, the Quebec Cancer Consortium, Ovarian Cancer Canada, IVADO-Genome Quebec and the Famille Sabourin Research Chair.


This multidisciplinary theme brings together clinicians, basic researchers and epidemiologists. Its current activities are grouped into six sub-themes. Treatment and chemoprevention  This sub-theme, plays a front line role through the development of new treatments and chemotherapies targeting…

Learn more